Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP ...

Dostarlimab effectively eliminates the need for surgery in patients with advanced mismatch repair-deficient (dMMR) tumors, ...

Actuate's lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs ...

Temel is an American Cancer Society Clinical Research Professor; co-authors reported relationships with, and/or support from, the Leukemia and Lymphoma Society, Incyte, GSK, AIM Pathways ...

The results were featured at the American Society of Haematology (ASH) annual meeting and, according to GSK, "support the potential ... treatment for the blood cancer. After being all but written ...

and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

The U.S. Food and Drug Administration this week granted permission for the use of a new cancer drug from China despite ...

Alabama State University’s Cancer Research Center hosted two American Cancer Society (ACS) officials for a second site visit as part of their grant review process.

Every 2 years, researchers from the American Cancer Society (ACS) publish a comprehensive report using data from multiple ...

"We are excited to partner with Besitos to engage a new audience in a new way and bring even greater hope to cancer patients and their families," said ACS Florida Vice President, Wendy Johnson. "This ...